Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
Premier American Uranium Completes US$5 Million Strategic Equity Investment by DISA Uranium; IsoEnergy Increases its Strategic Holding
